Gilead, Boehring Ingelheim and Takeda have contributed to a $59.6m round for Hookipa, a developer of immunotherapies for infectious diseases and cancer.
Austria-based immunotherapy developer Hookipa Biotech closed a $59.6m series C round yesterday featuring pharmaceutical companies Gilead Sciences, Boehringer Ingelheim and Takeda.
The round was led by an undisclosed investment fund with participation from HBM Partners, Hillhouse Capital, Sirona Capital, Sofinnova Partners, Forbion Capital Partners and BioMedPartners.
Boehringer and Takeda contributed through their respective corporate venturing units, Boehringer Ingelheim Venture Fund and Takeda Ventures.
Founded in 2011, Hookipa is developing immunotherapies to treat infectious diseases and cancer by infecting dendritic cells,…